Morning Briefing
Summaries of health policy coverage from major news organizations
Study Says High-Cost Cancer Drugs Have Little Benefit, Strain Health System
Using data from other published studies, researchers have estimated that lung-cancer drug Erbitux extends patients' lives by only 1.2 months, while costing $80,000 for an 18-week course of treatment.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
